Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia

JAMA

Volumn 311, Issue 21, 2014, Pages 2199-2208

  Mortensen, Eric M ^a,b   Halm, Ethan A ^b   Pugh, Mary Jo ^d,e   Copeland, Laurel A ^g   Metersky, Mark ^h   Fine, Michael J ^f   Johnson, Christopher S ^a,b   Alvarez, Carlos A ^a,b,c   Frei, Christopher R ^e,i   Good, Chester ^f   Restrepo, Marcos I ^d,e   Downs, John R ^d,e   Anzueto, Antonio ^d,e  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

ⁱ UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; DOXYCYCLINE;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SOCIOECONOMICS; SURVIVAL RATE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HOSPITALS, VETERANS; HUMANS; INPATIENTS; MALE; PNEUMONIA; RETROSPECTIVE STUDIES; RISK; UNITED STATES;

EID: 84901775962     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.4304     Document Type: Article

References (45)

1. Heron M. Deaths: leading causes for 2008. Natl Vital Stat Rep. 2012;60(6):1-94.
2. Mandell LA,Wunderink RG, Anzueto A, et al Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72. (Pubitemid 46290553)
3. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999;159(21):2562-2572.
4. Stahl JE, Barza M, DesJardin J, Martin R, Eckman MH. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med. 1999;159(21):2576-2580.
5. Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest. 2001;119(5):1420-1426. (Pubitemid 32686024)
6. Frei CR, Restrepo MI, Mortensen EM, Burgess DS. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med. 2006;119(10):865-871. (Pubitemid 44415611)
7. Asadi L, SliglWI, Eurich DT, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2012;55(3):371-380.
8. Matsunaga N, Oki Y, Prigollini A. A case of QT-interval prolongation precipitated by azithromycin. N Z Med J. 2003;116(1185):U666.
9. Huang BH,Wu CH, Hsia CP, Yin Chen C. Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol. 2007;30(12):1579-1582. (Pubitemid 350198276)
10. RayWA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881-1890.
11. Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med. 2013;368(18):1704-1712.
12. O'Connor CM, DunneMW, Pfeffer MA, et al Investigators in the WIZARD Study. Azithromycin for the secondary prevention of coronary heart disease events: theWIZARD study: a randomized controlled trial. JAMA. 2003;290(11):1459-1466. (Pubitemid 37430400)
13. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the Azithromycin in Coronary Artery Disease: Elimination ofMyocardial Infection with Chlamydia (ACADEMIC) study. Circulation. 1999;99(12):1540-1547. (Pubitemid 29152919)
14. Meehan TP, FineMJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997;278(23):2080-2084. (Pubitemid 28016230)
15. Mortensen EM, Restrepo M, Anzueto A, Pugh J. Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med. 2004;117(10):726-731. (Pubitemid 39482525)
16. SohnMW, Arnold N,Maynard C, Hynes DM. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr. 2006;4:2.
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
18. Kazis LE, Miller DR, Clark J, et al. Health-related quality of life in patients served by the Department of Veterans Affairs: results from the Veterans Health Study. Arch Intern Med. 1998;158(6):626-632. (Pubitemid 28144820)
19. Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med. 2002;162(9):1059-1064. (Pubitemid 34492537)
20. Perry TW, Pugh MJ,Waterer GW, et al. Incidence of cardiovascular events after hospital admission for pneumonia. Am J Med. 2011;124(3):244-251.
21. Leuven E, Sianesi B. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing [version 4.0.5]. http://ideas.repec.org/c/boc/bocode/s432001.html. Accessed May 12, 2014.
22. Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. J Health Econ. 2008;27(3):531-543.
23. Angrist J, Pischke JS. Mostly Harmless Econometrics: An Empiricist's Companion. Princeton, NJ: Princeton University Press; 2009.
24. Owens RC Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis. 2006;43(12):1603-1611. (Pubitemid 44910994)
25. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007;45(2):158-165. (Pubitemid 47041005)
26. Ramirez J, Aliberti S, Mirsaeidi M, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis. 2008;47(2):182-187. (Pubitemid 351920618)
27. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther. 2000;292(1):156-163. (Pubitemid 30026366)
28. LabroMT. Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother. 1998;41(suppl B):37-46. (Pubitemid 28152222)
29. Culić O, Eraković V, Cepelak I, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol. 2002;450(3):277-289.
30. Culić O, Eraković V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol. 2001;429(1-3):209-229. (Pubitemid 33043997)
31. Kadota J, Mukae H, Ishii H, et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med. 2003;97(7):844-850. (Pubitemid 36763898)
32. Kudoh S, Azuma A, YamamotoM, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157(6 pt 1):1829-1832.
33. YamamotoM, Kondo A, TamuraM, Izumi T, Ina Y, Noda M. Long-term therapeutic effects of erythromycin and new quinolone antibacterial agents on diffuse panbronchiolitis [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi. 1990;28(10):1305-1313.
34. Ashitani J, Mukae H, NakazatoM, et al. Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis. Eur Respir J. 1998;11(1):104-111. (Pubitemid 28081803)
35. Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med. 2004;117(suppl 9A):5S-11S.
36. Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Arch Intern Med. 2002;162(6):682-688. (Pubitemid 34226395)
37. Martínez JA, Horcajada JP, AlmelaM, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003;36(4):389-395. (Pubitemid 36241302)
38. Waterer GW, Somes GW,Wunderink RG. Monotherapymay be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med. 2001;161(15):1837- 1842. (Pubitemid 32762726)
39. Rodríguez A, Mendia A, Sirvent JM, et al CAPUCI Study Group. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med. 2007;35(6):1493-1498. (Pubitemid 46809312)
40. Restrepo MI, Mortensen EM,Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2009;33(1):153-159.
41. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The impact of empiric antimicrobial therapy with a beta-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care. 2005;10(1):R8.
42. Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2007;51(11):3977-3982. (Pubitemid 350057796)
43. Wilson BZ, Anzueto A, Restrepo MI, Pugh MJ, Mortensen EM. Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia. Crit Care Med. 2012;40(8):2310-2314.
44. Metersky ML,Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest. 2007;131(2):466-473. (Pubitemid 46280407)
45. Smith Sehdev AE, Hutchins GM. Problems with proper completion and accuracy of the cause-of-death statement. Arch Intern Med. 2001;161(2):277-284. (Pubitemid 32102397)